Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that market penetration in the United States of Roche/Genentech/Chugai's Avastin and the launches of expensive targeted agents from ImClone/Merck Serono, AstraZeneca, and Bayer/Onyx will drive robust near-term growth in the non-small-cell lung cancer (NSCLC) drug market.

The new Pharmacor report Non-Small-Cell Lung Cancer finds that the launch of Avastin in the United States in 2006 (and its imminent launch in Europe) and the expected launches of ImClone/Merck Serono's Erbitux and AstraZeneca's Zactima for patients with chemotherapy-refractory NSCLC, as well as AstraZeneca's Recentin and Bayer/Onyx's Nexavar for first-line treatment in all major markets, will drive 16% annual growth through 2011.

Near-term market growth will also be spurred by the launches of two novel immunotherapies that will offer additional treatment options - Merck Serono's Stimuvax for treating stage III patients and Pfizer's ProMune for treating advanced-stage patients. However, owing to generics erosion and competition among multiple new drug entrants, the report forecasts that the market will plateau between 2011 and 2016.

"The major factors underlying market growth are the widespread uptake of vascular endothelial growth factor (VEGF) inhibitors such as Avastin and the launches of novel immunotherapies," said Mohamed Muhsin, analyst at Decision Resources. "The uptake of Avastin has made an incremental step toward improving the prognosis of patients with non-small-cell lung cancer but significant unmet clinical need still exists for a treatment that would further improve the prognosis of patients."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Despite Recent Negative Media Coverage Regarding Plavix, Bristol-Myers Squibb Remains Number One Cardiovascular Drug Company for Surveyed Physicians

View Now